Beyond the Congress - 2022 Agenda

Friday, February 4, 2022

Target Audience

Oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists charged with the care of the patient with hematologic malignancies

Educational Objectives

Coming Soon!

Time (EST)
9:30 am – 9:40 am
Welcome and meeting overview
John Leonard, MD
Lymphoma Session
9:40 am – 9:55 am
New data in upfront and relapsed aggressive B-cell lymphoma
John Leonard, MD
9:55 am – 10:10 am
What’s new in therapy of indolent and mantle cell lymphoma
Brad Kahl, MD
10:10 am – 10:25 am
Updates in the management of Hodgkin and T-cell lymphomas

Sonali Smith, MD

10:25 am – 10:40 am
Key Conversations: Lymphoma panel discussion and Q&A moderated by Dr. Leonard
Break for Exhibits and Posters (15 minutes)
Multiple Myeloma and CAR T-Cell Therapy Session
10:55 am – 11:10 am
New data in upfront management of multiple myeloma
Sagar Lonial, MD, FACP
11:10 am – 11:25 am
How to integrate novel approached in the treatment of relapsed/refractory myeloma
Kenneth Anderson, MD
11:25 am – 11:40 am
What are the latest approaches for using CAR T-cell therapy for multiple myeloma ?
Nina Shah, MD
11:40 am – 11:55 am
Key Conversations: Multiple myeloma panel discussion and Q&A moderated by Dr. Lonial
CLL Session
12:25 pm – 12:40 pm
New therapeutic options in frontline CLL
Susan O’Brien, MD
12:40 pm – 12:55 pm
Updates in management for relapsed and refractory CLL
Jennifer Brown, MD, PhD
12:55 pm – 1:10 pm
Nitin Jain, MD
1:10 pm – 1:25 pm
Key Conversations: CLL panel discussion and Q&A moderated by Dr. O’Brien
Acute Leukemia Session
1:40 pm – 1:55 pm
What’s new in upfront treatment of AML
Selina Luger, MD
1:55 pm – 2:10 pm
New direction in the treatment of relapsed and refractory AML
Courtney DiNardo, MD
2:10 pm – 2:25 pm
Hot topics in the management of AML
Eunice Wang, MD
2:25 pm – 2:40 pm
Key Conversations: Acute leukemia panel discussion and Q&A moderated by Dr. Luger
MDS/MPN Session
2:55 pm – 3:10 pm
New treatments for MPNs, CML and systemic mastocytosis
Ellen Ritchie, MD
3:10 pm – 3:25 pm
Updates in the management of MDS
Mike Savona, MD
3:25 pm – 3:40 pm
New developments in nonmalignant hematology
Katherine Walsh, MD
3:40 pm – 3:55 pm
Key Conversations: MDS/MPN panel discussion and Q&A moderated by Dr. Ritchie
3:55 pm – 4:00 pm
Closing summary and post session survey
John Leonard, MD